Myoblast autologous graft ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 113 | Muscular dystrophy | 1 |
113. Muscular dystrophy
Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02878694 (ClinicalTrials.gov) | November 14, 2019 | 8/3/2016 | Treatment of Ptosis to Muscular Dystrophy Oculopharyngeal by Myoblast Autologous Graft | Treatment of Ptosis to Muscular Dystrophy Oculopharyngeal by Myoblast Autologous Graft | Muscular Dystrophy, Oculopharyngeal;Ptosis | Biological: Myoblast autologous graft | University Hospital, Caen | University Hospital, Rouen;Rennes University Hospital;Centre Hospitalier Universitaire, Amiens;University Hospital, Lille;University Hospital, Brest;Groupe Hospitalier Pitie-Salpetriere | Terminated | 18 Years | 75 Years | All | 1 | Phase 2/Phase 3 | France |